Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $8.6 million versus the consensus estimate of $4.01 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.